Evidence map›Paper›PMID 39475070›Full record

ArticleAdvanced healthcare materials2025

Multi-Target Peptide Nanofiber Immunotherapy Diminishes Complement Anaphylatoxin Activity in Acute Inflammation.

Helena Freire Haddad, Emily F Roe, Vinicius Xie Fu, Elizabeth J Curvino, Joel H Collier

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Helena Freire HaddadDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Emily F RoeDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Vinicius Xie FuDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Elizabeth J CurvinoDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Joel H CollierDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.ORCID 0000-0003-3536-4827

Funding

Supramolecular biomaterials for tuning the inflammatory properties of the complement systemR01AI172151 · NIAID · DUKE UNIVERSITY · PI COLLIER, JOEL H · 2022 to 2025
$2.8M
Duke UniversityNational Science Foundation DGE-1644868NIAID NIH HHS R01 AI172151NIH HHS 1 R01 AI172151
6 · The paper itself

Abstract

The anaphylatoxins C3a and C5a are products of the complement cascade that play important and interrelated roles in health and disease. Both are potential targets for anti-inflammatory active immunotherapies in which a patient's own immune system is stimulated to produce therapeutic immune responses against problematic self-molecules. However, the complex and time-dependent interrelations between the two molecules make dual targeting challenging. To investigate a dual-target active immunotherapy against C3a and C5a and to systematically study the effect of varied degrees of responses against both targets, the study employed self-assembled peptide immunogens capable of displaying a broad range of epitope compositions and Design-of-Experiments (DoE) approaches. Peptide nanofibers contained B-cell epitopes of C3a and C5a in defined quantities, and intranasal immunization raised systemic and mucosal immunity against each target. In a lipopolysaccharide-induced model of sepsis, increasing anti-C5a responses are protective, whereas increasing anti-C3a responses are detrimental, and survival rates are negatively correlated with anti-C3a/anti-C5a IgG titer ratio. This work highlights the interplay between the two molecules by making use of a modular, defined, and easily adjusted biomaterial-based active immunotherapy platform.

Indexed as

ImmunotherapyInflammationNanofibersPeptidesAnaphylatoxinsAnimalsComplement C3aComplement C5aFemaleLipopolysaccharidesMiceMice, Inbred C57BLSepsisAnaphylatoxinsComplement C3aComplement C5aLipopolysaccharidesPeptidesimmune engineeringimmunoengineeringimmunotherapyself‐assemblysupramolecular

Identifiers

PMID39475070
PMCPMC11695164

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.